Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

Fig. 3

Subsequent treatments in a intention-to-treat population and b overall survival for subsequent treatments. E erlotinib, GC gemcitabine plus cisplatin, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, PFS progression-free survival, NC not calculable

Back to article page